Tokai quickly tosses most of its staff after PhIII cancer drug fails
Tokai Pharmaceuticals’ execs have decided that they can no longer afford most of their staff. Just three days after revealing that their prostate cancer drug galeterone had failed a Phase III study, the biotech says it will cut 60% of its staff and reduce its payroll to the equivalent of 10 full time people.
The biotech $TKAI slammed the brakes on its ARMOR3-SV study after the data monitoring committee concluded that the drug proved to be a dud, effectively shredding Tokai’s business plan.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
